. Referanser

Bello, M. J., Alonso, M. E., Aminoso, C., Anselmo, N. P., Arjona, D., Gonzalez-Gomez, P., . . . Rey, J. A. (2004). Hypermethylation of the DNA repair gene MGMT: association with TP53 G:C to A:T transitions in a series of 469 nervous system tumors. Mutation Research, 554(1-2), 23-32. https://doi.org/10.1016/j.mrfmmm.2004.02.011

Berghoff, A., & van den Bent, M. (2019). How I treat anaplastic glioma without 1p/19q codeletion. ESMO Open, 4(Suppl 2), e000534. https://doi.org/10.1136/esmoopen-2019-000534

Bleehen, N. M., & Stenning, S. P. (1991). A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. British Journal of Cancer, 64(4), 769-774.

Blumenthal, D. T., Won, M., Mehta, M. P., Curran, W. J., Souhami, L., Michalski, J. M., . . . Corn, B. W. (2009). Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. Journal of Clinical Oncology, 27(5), 733-739. https://doi.org/10.1200/jco.2008.18.9035

Blumenthal, D. T., Yalon, M., Vainer, G. W., Lossos, A., Yust, S., Tzach, L., . . . Bokstein, F. (2016). Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. Journal of Neuro-Oncology, 129(3), 453-460. https://doi.org/10.1007/s11060-016-2190-1

Brandsma, D., & van den Bent, M. J. (2009). Pseudoprogression and pseudoresponse in the treatment of gliomas. Current Opinion in Neurology, 22(6), 633-638. https://doi.org/10.1097/WCO.0b013e328332363e

Brat, D. J., Aldape, K., Colman, H., Holland, E. C., Louis, D. N., Jenkins, R. B., . . . Weller, M. (2018). cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathologica, 136(5), 805-810. https://doi.org/10.1007/s00401-018-1913-0

Buglione, M., Pedretti, S., Poliani, P. L., Liserre, R., Gipponi, S., Spena, G., . . . Magrini, S. M. (2016). Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: Could a margin reduction be proposed? Journal of Neuro-Oncology, 128(2), 303-312. https://doi.org/10.1007/s11060-016-2112-2

Cabrera, A. R., Kirkpatrick, J. P., Fiveash, J. B., Shih, H. A., Koay, E. J., Lutz, S., . . . Chang, E. (2016). Radiation therapy for glioblastoma: Executive summary of an American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline. Practical Radiation Oncology, 6(4), 217-225. https://doi.org/10.1016/j.prro.2016.03.007

Cairncross, G., Berkey, B., Shaw, E., Jenkins, R., Scheithauer, B., Brachman, D., . . . Curran, W. (2006). Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology, 24(18), 2707-2714. https://doi.org/10.1200/jco.2005.04.3414

Cairncross, G., Wang, M., Shaw, E., Jenkins, R., Brachman, D., Buckner, J., . . . Mehta, M. (2013). Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology, 31(3), 337-343. https://doi.org/10.1200/jco.2012.43.2674

Cao, J. Q., Fisher, B. J., Bauman, G. S., Megyesi, J. F., Watling, C. J., & Macdonald, D. R. (2012). Hypofractionated radiotherapy with or without concurrent temozolomide in elderly patients with glioblastoma multiforme: a review of ten-year single institutional experience. Journal of Neuro-Oncology, 107(2), 395-405. https://doi.org/10.1007/s11060-011-0766-3

Chang, E. L., Akyurek, S., Avalos, T., Rebueno, N., Spicer, C., Garcia, J., . . . Maor, M. H. (2007). Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. International Journal of Radiation Oncology, Biology, Physics, 68(1), 144-150. https://doi.org/10.1016/j.ijrobp.2006.12.009

Chinot, O. L., Wick, W., Mason, W., Henriksson, R., Saran, F., Nishikawa, R., . . . Cloughesy, T. (2014). Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 709-722. https://doi.org/10.1056/NEJMoa1308345

Darlix, A., Baumann, C., Lorgis, V., Ghiringhelli, F., Blonski, M., Chauffert, B., . . . Taillandier, L. (2013). Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Research, 33(8), 3467-3474.

Fogh, S. E., Andrews, D. W., Glass, J., Curran, W., Glass, C., Champ, C., . . . Werner-Wasik, M. (2010). Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. Journal of Clinical Oncology, 28(18), 3048-3053. https://doi.org/10.1200/jco.2009.25.6941

Forskrift om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften). FOR-2000-12-01-1208. Last update in FOR-2020-02-04-119 fra 01.03.2020. Retrieved from https://lovdata.no/dokument/SF/forskrift/2000-12-01-1208

Frischer, J. M., Marosi, C., Woehrer, A., Hainfellner, J. A., Dieckmann, K. U., Eiter, H., . . . Gatterbauer, B. (2016). Gamma Knife Radiosurgery in Recurrent Glioblastoma. Stereotactic and Functional Neurosurgery, 94(4), 265-272. https://doi.org/10.1159/000448924

Galldiks, N., Langen, K. J., & Pope, W. B. (2015). From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? Neuro-Oncology, 17(11), 1434-1444. https://doi.org/10.1093/neuonc/nov118

Galldiks, N., Law, I., Pope, W. B., Arbizu, J., & Langen, K. J. (2017). The use of amino acid PET and conventional MRI for monitoring of brain tumor therapy. Neuroimage Clin, 13, 386-394. https://doi.org/10.1016/j.nicl.2016.12.020

Gebhardt, B. J., Dobelbower, M. C., Ennis, W. H., Bag, A. K., Markert, J. M., & Fiveash, J. B. (2014). Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiation Oncology (London, England), 9, 130. https://doi.org/10.1186/1748-717x-9-130

Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., . . . Mehta, M. P. (2014). A randomized trial of bevacizumab for newly diagnosed glioblastoma. New England Journal of Medicine, 370(8), 699-708. https://doi.org/10.1056/NEJMoa1308573

Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., . . . Mehta, M. P. (2013). Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. Journal of Clinical Oncology, 31(32), 4085-4091. https://doi.org/10.1200/jco.2013.49.6968

Guseynova, K., Liscak, R., Simonova, G., & Novotny, J., Jr. (2018). Gamma knife radiosurgery for local recurrence of glioblastoma. Neuro Endocrinology Letters, 39(4), 281-287.

Hart, M. G., Garside, R., Rogers, G., Stein, K., & Grant, R. (2013). Temozolomide for high grade glioma. Cochrane Database of Systematic Reviews, (4), CD007415. https://doi.org/10.1002/14651858.CD007415.pub2

Herrlinger, U., Tzaridis, T., Mack, F., Steinbach, J. P., Schlegel, U., Sabel, M., . . . Glas, M. (2019). Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet, 393(10172), 678-688. https://doi.org/10.1016/s0140-6736(18)31791-4

Ichimura, K., Narita, Y., & Hawkins, C. E. (2015). Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. Acta Neuropathologica, 129(6), 789-808. https://doi.org/10.1007/s00401-015-1439-7

Imber, B. S., Kanungo, I., Braunstein, S., Barani, I. J., Fogh, S. E., Nakamura, J. L., . . . Aghi, M. K. (2017). Indications and Efficacy of Gamma Knife Stereotactic Radiosurgery for Recurrent Glioblastoma: 2 Decades of Institutional Experience. Neurosurgery, 80(1), 129-139. https://doi.org/10.1227/neu.0000000000001344

Jansen, E. P., Dewit, L. G., van Herk, M., & Bartelink, H. (2000). Target volumes in radiotherapy for high-grade malignant glioma of the brain. Radiotherapy and Oncology, 56(2), 151-156.

Johnson, D. R., Leeper, H. E., & Uhm, J. H. (2013). Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: a population-based analysis. Cancer, 119(19), 3489-3495. https://doi.org/10.1002/cncr.28259

Keime-Guibert, F., Chinot, O., Taillandier, L., Cartalat-Carel, S., Frenay, M., Kantor, G., . . . Delattre, J. Y. (2007). Radiotherapy for glioblastoma in the elderly. New England Journal of Medicine, 356(15), 1527-1535. https://doi.org/10.1056/NEJMoa065901

Kleinschmidt-DeMasters, B. K., & Mulcahy Levy, J. M. (2018). H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis. Clinical Neuropathology, 37 (2018)(2), 53-63. https://doi.org/10.5414/np301085

Korshunov, A., Casalini, B., Chavez, L., Hielscher, T., Sill, M., Ryzhova, M., . . . Sahm, F. (2019). Integrated molecular characterization of IDH-mutant glioblastomas. Neuropathology and Applied Neurobiology, 45(2), 108-118. https://doi.org/10.1111/nan.12523

Kruser, T. J., Mehta, M. P., & Robins, H. I. (2013). Pseudoprogression after glioma therapy: a comprehensive review. Expert Review of Neurotherapeutics, 13(4), 389-403. https://doi.org/10.1586/ern.13.7

Landberg, T., Chavaudra, J., Dobbs, J., Gerard, J. P., Hanks, G., Horiot, J. C., . . . Svensson, H. (1999). Report 62: prescribing, Recording and Reporting Photon Beam Therapy (Supplement to ICRU report 50). Journal of the International Commission on Radiation Units and Measurements, os32(1).

Landberg, T., Chavaudra, J., Dobbs, J., Hanks, G., Johansson, K.-A., Möller, T., & Purdy, J. (1993). Report 50: Prescribing, Recording, and Reporting Photon Beam Therapy. Journal of the International Commission on Radiation Units and Measurements, os26(1).

Laperriere, N., Zuraw, L., & Cairncross, G. (2002). Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiotherapy and Oncology, 64(3), 259-273.

Larsen, I. K. (Ed.). (2016). Cancer in Norway 2015 - cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway. Retrieved from https://www.kreftregisteret.no/globalassets/cancer-in-norway/2015/cin2015-special_issue-web.pdf

Lawrence, Y. R., Blumenthal, D. T., Matceyevsky, D., Kanner, A. A., Bokstein, F., & Corn, B. W. (2011). Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line? Journal of Neuro-Oncology, 105(1), 1-7. https://doi.org/10.1007/s11060-011-0589-2

Leve med kreft: nasjonal kreftstrategi (2018–2022). (2018). Oslo: Helse- og omsorgsdepartementet. Retrieved from https://www.regjeringen.no/no/dokumenter/leve-med-kreft/id2598282/

Levernes, S. (2012). Volum og doser i ekstern stråleterapi: definisjoner og anbefalinger (StrålevernRapport 2012:9). Østerås: Statens strålevern. Retrieved from https://dsa.no/medisinsk-stralebruk/kvist/_/attachment/download/bee8860b-36d1-42e7-8d64-f5ad4fcef2e8:8ebb86decddc2818ec31e4999d26cdf7aec14ac2/StralevernRapport_09-2012.pdf

Levernes, S. (2019). Faglige anbefalinger for nomenklatur for volumer i stråleterapi (Teknisk dokument 14). Østerås: Direktoratet for strålevern og atomsikkerhet. Retrieved from https://dsa.no/publikasjoner/_/attachment/download/9d2a42a5-241e-4299-86cf-6b02a0abf3b9:2400dff7cb71f4bff583473d690fcb79650dd59e/TekniskDokument14_rev2020.pdf

Levin, V. A., Bidaut, L., Hou, P., Kumar, A. J., Wefel, J. S., Bekele, B. N., . . . Jackson, E. F. (2011). Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. International Journal of Radiation Oncology, Biology, Physics, 79(5), 1487-1495. https://doi.org/10.1016/j.ijrobp.2009.12.061

Levin, V. A., Mendelssohn, N. D., Chan, J., Stovall, M. C., Peak, S. J., Yee, J. L., . . . Chen, D. M. (2015). Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma. Journal of Neuro-Oncology, 122(1), 145-150. https://doi.org/10.1007/s11060-014-1693-x

Louis, D. N., Ohgaki, H., Wiestler, O. W., & Cavenee, W. K. (Eds.). (2016). WHO classification of tumours of the central nervous system (4. rev. ed.). (Tumours of the Central nervous system). Lyon: IARC Press.

Lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven). LOV-2011-06-24-30. Last update in LOV-2019-06-21-45 fra 01.01.2020. Retrieved from https://lovdata.no/dokument/NL/lov/2011-06-24-30

Lov om pasient- og brukerrettigheter (pasient- og brukerrettighetsloven). LOV-1999-07-02-63. Last update in LOV-2019-12-20-104 fra 01.03.2020. Retrieved from https://lovdata.no/dokument/NL/lov/1999-07-02-63

Malmström, A., Grønberg, B. H., Marosi, C., Stupp, R., Frappaz, D., Schultz, H., . . . Henriksson, R. (2012). Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncology, 13(9), 916-926. https://doi.org/10.1016/s1470-2045(12)70265-6

Marienhagen, K., Djupvik, L. H., & Danielsen, T. (2020). Faglige anbefalinger for inntegning av risikoorganer i CNS (Teknisk dokument 16). Østerås: Direktoratet for strålevern og atomsikkerhet. Retrieved from https://dsa.no/publikasjoner/_/attachment/download/401a60b3-b7db-4c4a-b741-da0a70c43b20:f0c3325a0ec4a43b2335cf17df266e4e7c34408c/Teknisk%20dokument16_rev.pdf

Mayer, R., & Sminia, P. (2008). Reirradiation tolerance of the human brain. International Journal of Radiation Oncology, Biology, Physics, 70(5), 1350-1360. https://doi.org/10.1016/j.ijrobp.2007.08.015

Minniti, G., Scaringi, C., Arcella, A., Lanzetta, G., Di Stefano, D., Scarpino, S., . . . Enrici, R. M. (2014). IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of Neuro-Oncology, 118(2), 377-383. https://doi.org/10.1007/s11060-014-1443-0

Minniti, G., Scaringi, C., Baldoni, A., Lanzetta, G., De Sanctis, V., Esposito, V., & Enrici, R. M. (2013). Health-related quality of life in elderly patients with newly diagnosed glioblastoma treated with short-course radiation therapy plus concomitant and adjuvant temozolomide. International Journal of Radiation Oncology, Biology, Physics, 86(2), 285-291. https://doi.org/10.1016/j.ijrobp.2013.02.013

Nasjonal helseplan (2007–2010). (2006). (Særtrykk av St.prp. nr. 1 (2006–2007) kapittel 6). Oslo: Helse- og omsorgsdepartementet. Retrieved from https://www.regjeringen.no/globalassets/upload/hod/sykehus/nasjonal_helseplan_sartrykk.pdf

Nasjonal strategi for kreftområdet 2006-2009. (2006). Oslo: Helse- og omsorgsdepartementet. Retrieved from https://www.regjeringen.no/no/dokumenter/nasjonal-strategi-for-kreftomradet/id446845/

Nelson, D. F., Diener-West, M., Horton, J., Chang, C. H., Schoenfeld, D., & Nelson, J. S. (1988). Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monographs, (6), 279-284.

Niyazi, M., Brada, M., Chalmers, A. J., Combs, S. E., Erridge, S. C., Fiorentino, A., . . . Belka, C. (2016). ESTRO-ACROP guideline "target delineation of glioblastomas". Radiotherapy and Oncology, 118(1), 35-42. https://doi.org/10.1016/j.radonc.2015.12.003

Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., . . . Sampsonc, J. H. (2018). Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase 1 cohorts of CheckMate 143. Neuro-Oncology, 20(5), 674-686. https://doi.org/10.1093/neuonc/nox208

Perry, J. R., Laperriere, N., O'Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., . . . Mason, W. P. (2017). Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma. New England Journal of Medicine, 376(11), 1027-1037. https://doi.org/10.1056/NEJMoa1611977

Phillips, C., Guiney, M., Smith, J., Hughes, P., Narayan, K., & Quong, G. (2003). A randomized trial comparing 35Gy in ten fractions with 60Gy in 30 fractions of cerebral irradiation for glioblastoma multiforme and older patients with anaplastic astrocytoma. Radiotherapy and Oncology, 68(1), 23-26.

Puntonet, J., Dangouloff-Ros, V., Saffroy, R., Pages, M., Andreiuolo, F., Grill, J., . . . Varlet, P. (2018). Historadiological correlations in high-grade glioma with the histone 3.3 G34R mutation. Journal of Neuroradiology. Journal de Neuroradiologie, 45(5), 316-322. https://doi.org/10.1016/j.neurad.2018.02.006

Report 78: Prescribing, Recording, and Reporting Proton-Beam Therapy. (2007). Journal of the International Commission on Radiation Units and Measurements, 7(7).

Report 83: Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT). (2010). Journal of the International Commission on Radiation Units and Measurements, 10(1).

Ryu, S., Buatti, J. M., Morris, A., Kalkanis, S. N., Ryken, T. C., & Olson, J. J. (2014). The role of radiotherapy in the management of progressive glioblastoma : A systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology, 118(3), 489-499. https://doi.org/10.1007/s11060-013-1337-6

Rønning, P. A., Helseth, E., Meling, T. R., & Johannesen, T. B. (2012). A population-based study on the effect of temozolomide in the treatment of glioblastoma multiforme. Neuro-Oncology, 14(9), 1178-1184. https://doi.org/10.1093/neuonc/nos153

Sammen - mot kreft: nasjonal kreftstrategi 2013-2017. (2013). Oslo: Helse- og omsorgsdepartementet. Retrieved from https://www.iccp-portal.org/system/files/plans/kreftstrategien_2013.pdf

Sanson, M., Marie, Y., Paris, S., Idbaih, A., Laffaire, J., Ducray, F., . . . Delattre, J. Y. (2009). Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. Journal of Clinical Oncology, 27(25), 4150-4154. https://doi.org/10.1200/jco.2009.21.9832

Scoccianti, S., Magrini, S. M., Ricardi, U., Detti, B., Krengli, M., Parisi, S., . . . Biti, G. (2012). Radiotherapy and temozolomide in anaplastic astrocytoma: a retrospective multicenter study by the Central Nervous System Study Group of AIRO (Italian Association of Radiation Oncology). Neuro-Oncology, 14(6), 798-807. https://doi.org/10.1093/neuonc/nos081

Sharma, R. R., Singh, D. P., Pathak, A., Khandelwal, N., Sehgal, C. M., Kapoor, R., . . . Sharma, S. C. (2003). Local control of high-grade gliomas with limited volume irradiation versus whole brain irradiation. Neurology India, 51(4), 512-517.

Siker, M. L., Chakravarti, A., & Mehta, M. P. (2006). Should concomitant and adjuvant treatment with temozolomide be used as standard therapy in patients with anaplastic glioma? Critical Reviews in Oncology/Hematology, 60(2), 99-111. https://doi.org/10.1016/j.critrevonc.2006.04.005

Solheim, O., Gulati, S., & Jakola, A. S. (2014). Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-Oncology, 16(4), 610-611. https://doi.org/10.1093/neuonc/not312

Stewart, L. A. (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet, 359(9311), 1011-1018.

Stummer, W., Reulen, H. J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J. C., . . . Pietsch, T. (2008). Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery, 62(3), 564-576; discussion 564-576. https://doi.org/10.1227/01.neu.0000317304.31579.17

Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., . . . Mirimanoff, R. O. (2009). Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncology, 10(5), 459-466. https://doi.org/10.1016/s1470-2045(09)70025-7

Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., . . . Mirimanoff, R. O. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987-996. https://doi.org/10.1056/NEJMoa043330

Stupp, R., Reni, M., Gatta, G., Mazza, E., & Vecht, C. (2007). Anaplastic astrocytoma in adults. Critical Reviews in Oncology/Hematology, 63(1), 72-80. https://doi.org/10.1016/j.critrevonc.2007.03.003

Stupp, R., Taillibert, S., Kanner, A. A., Kesari, S., Steinberg, D. M., Toms, S. A., . . . Ram, Z. (2015). Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. JAMA, 314(23), 2535-2543. https://doi.org/10.1001/jama.2015.16669

Taal, W., Oosterkamp, H. M., Walenkamp, A. M., Dubbink, H. J., Beerepoot, L. V., Hanse, M. C., . . . van den Bent, M. J. (2014). Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncology, 15(9), 943-953. https://doi.org/10.1016/s1470-2045(14)70314-6

van den Bent, M. J., Baumert, B., Erridge, S. C., Vogelbaum, M. A., Nowak, A. K., Sanson, M., . . . Kros, J. M. (2017). Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study. Lancet, 390(10103), 1645-1653. https://doi.org/10.1016/s0140-6736(17)31442-3

van den Bent, M. J., Brandes, A. A., Taphoorn, M. J., Kros, J. M., Kouwenhoven, M. C., Delattre, J. Y., . . . Hoang-Xuan, K. (2013). Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of Clinical Oncology, 31(3), 344-350. https://doi.org/10.1200/jco.2012.43.2229

van den Bent, M. J., Carpentier, A. F., Brandes, A. A., Sanson, M., Taphoorn, M. J., Bernsen, H. J., . . . Gorlia, T. (2006). Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology, 24(18), 2715-2722. https://doi.org/10.1200/jco.2005.04.6078

van den Bent, M. J., Dubbink, H. J., Marie, Y., Brandes, A. A., Taphoorn, M. J., Wesseling, P., . . . Sanson, M. (2010). IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research, 16(5), 1597-1604. https://doi.org/10.1158/1078-0432.ccr-09-2902

van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M., Jeuken, J. W., . . . Kros, J. M. (2009). MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 27(35), 5881-5886. https://doi.org/10.1200/jco.2009.24.1034

van den Bent, M. J., Erridge, S., Vogelbaum, M. A., Nowak, A. K., Sanson, M., Brandes, A. A., . . . baumert, B. G. (2016). Results of the interim analsis of the EORTC randomized phase III  CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An intergroup trial. Journal of Clinical Oncology, 34 (18_suppl), abstract LBA2000.

van den Bent, M. J., Gravendeel, L. A., Gorlia, T., Kros, J. M., Lapre, L., Wesseling, P., . . . French, P. J. (2011). A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research, 17(22), 7148-7155. https://doi.org/10.1158/1078-0432.ccr-11-1274

Wallner, K. E., Galicich, J. H., Krol, G., Arbit, E., & Malkin, M. G. (1989). Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. International Journal of Radiation Oncology, Biology, Physics, 16(6), 1405-1409.

Weller, M., Pfister, S. M., Wick, W., Hegi, M. E., Reifenberger, G., & Stupp, R. (2013). Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncology, 14(9), e370-379. https://doi.org/10.1016/s1470-2045(13)70168-2

Weller, M., Stupp, R., Hegi, M. E., van den Bent, M., Tonn, J. C., Sanson, M., . . . Reifenberger, G. (2012). Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. Neuro-Oncology, 14 Suppl 4, iv100-108. https://doi.org/10.1093/neuonc/nos206

Wick, W., Gorlia, T., Bendszus, M., Taphoorn, M., Sahm, F., Harting, I., . . . van den Bent, M. J. (2017). Lomustine and Bevacizumab in Progressive Glioblastoma. New England Journal of Medicine, 377(20), 1954-1963. https://doi.org/10.1056/NEJMoa1707358

Wick, W., Meisner, C., Hentschel, B., Platten, M., Schilling, A., Wiestler, B., . . . Weller, M. (2013). Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology, 81(17), 1515-1522. https://doi.org/10.1212/WNL.0b013e3182a95680

Wick, W., Platten, M., Meisner, C., Felsberg, J., Tabatabai, G., Simon, M., . . . Weller, M. (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncology, 13(7), 707-715. https://doi.org/10.1016/s1470-2045(12)70164-x

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., . . . Bigner, D. D. (2009). IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine, 360(8), 765-773. https://doi.org/10.1056/NEJMoa0808710

Yoshimoto, K., Hatae, R., Sangatsuda, Y., Suzuki, S. O., Hata, N., Akagi, Y., . . . Iihara, K. (2017). Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. Brain Tumor Pathology, 34(3), 103-112. https://doi.org/10.1007/s10014-017-0287-7